SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer. Dr. Owen will be responsible for evolving and executing the clinical development programs for ACADIA’s product candidates and report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s Executive Vice President, Head of Research and Development.
